Gene Therapy Market – Snapshot
The global gene therapy market
is expanding at an exponential pace due to promising therapeutic
outcomes of gene therapy, high prevalence and rise in incidence of
cancer, and large number of clinical research pipeline products. In
terms of revenue, the market was valued at US$ 17.0 Mn in 2017. It is
projected to reach a value of US$ 5164.03 Mn by 2026, expanding at a
CAGR of 40.0% from 2018 to 2026. The global gene therapy market is
driven by new product approvals and commercialization, increasing demand
and number of gene therapy treatment centers, and large number of
patient population with unmet medical needs.
gene therapy market
Gene therapy is a way of fixing genetic
disorders by introducing a normal and healthy gene in place of defective
genes in a cell in order to prevent or cure different types of genetic
and chronic disorders for which no final cure has been developed. Gene
therapy is considered as an important means of treatment, as it helps
eliminate the usage of drugs, surgery, or other procedures that can have
side-effects on the health of individuals. Moreover, gene therapy
results in the formation of beneficial proteins that can help the body
perform normal functions to its full potential. Cell-based technologies
have been developing at a rapid pace, which in turn has driven the
demand for gene therapy. Till date, only five gene therapy products have
been approved and are currently in the infancy stage of
commercialization. Gendicine was the first commercialized gene therapy
product developed by the Shenzhen, China-based SiBiono GeneTech, in
2003. Gendicine was commercialized in China, in 2004.
The global market for gene therapy has
been expanding due to the intensive research that has offset in the
domain of genetics. Demand for gene therapy across the globe has
increased significantly due to the rise in awareness about the ability
of gene therapy to cure diseases. Gene therapy has considerable
potential to eliminate and prevent several genetic disorders and
numerous life-threatening disorders, especially cancer, heart diseases,
AIDS, cystic fibrosis, and age-related disorders. Gene therapy provides a
complete cure to patients affected with genetic disorders, rather than
ease symptoms with other therapeutic treatments. Promising therapeutic
outcomes and increasing competition among leading biopharmaceutical
companies to approve and commercialize gene therapy products in
different areas of unmet medical needs, in order to gain the first mover
advantage, are projected to boost the gene therapy market during the
forecast period. Moreover, high prevalence and rise in incidence rates
of different types of cancers for which complete cure has not been
developed is a key factor that is expected to drive the gene therapy
market.
Large number of gene therapy candidates
are in late stage clinical studies and are anticipated to commercialize
during the forecast period. Significant investments in the field of
gene-related research and development by various biopharmaceutical
companies, governments, as well as research institutes offers potential
opportunity to gain the first mover advantage in the gene therapy
market. According to Alliance for Regenerative Medicine, in 2015, more
than US$ 10 Bn has been invested by both public as well as private
companies in gene therapy-related research. Companies, after initial
success rates of gene therapy, are striving to increase the number of
treatment centers in order to increase the access to a large number of
patient pool requiring gene therapy treatments. Thus, increasing number
of gene therapy treatment centers in developed countries offers
significant opportunity to global players operating in the gene therapy
market.
The global gene therapy market has been
segmented based on product, application, and region. In terms of
product, there are only five gene therapy products that have been
approved and commercialized globally. These include Yescarta, Kymriah,
Luxturna, Strimvelis, and Gendicine. The Yescarta segment dominated the
global market in 2017. It is projected to gain market share by the end
of 2026. Yescarta bagged the first mover advantage in 2017 in the U.S,
by launching the first CAR T therapy approved by the US FDA for the
treatment of certain relapsed or refractory large B-cell lymphoma,
including diffuse large B-cell lymphoma (DLBCL). Furthermore, high
prevalence of DLBCL and anticipated commercialization of Yescarta in
Europe and other developed countries are projected to drive the demand
for Yescarta during the forecast period. The Luxturna segment is
projected to expand at a significant growth rate during the forecast
period.
Based on application, the global gene
therapy market has been divided into ophthalmology, oncology, and
adenosine deaminase ?deficient severe combined immunodeficiency
(ADA-SCID). The oncology segment accounted for a prominent share of the
market in 2017. Of the five gene therapy products approved, three
products are directed toward the treatment of certain forms of cancer.
Moreover, increased application of gene therapy products in treatment of
other forms of cancers is poised to drive the oncology segment during
the forecast period.
Based on region, the global gene therapy
market has been segmented into three major regions: U.S., Europe, and
Rest of World. Europe is projected to account for a dominant share of
more than 40% of the global market by 2026. Increasing number of gene
therapy treatment centers in the region and high prevalence and rising
incidence rates of non-Hodgkin lymphoma are projected to fuel the gene
therapy market in the region during the forecast period. The U.S. is
projected to follow Europe, in terms of share of global gene therapy
market, by the end of 2026. It is estimated that in the U.S., every
year, around 7,500 patients with refractory DLBCL are eligible for CART
therapy. The gene therapy market in Rest of World is projected to expand
at a notable CAGR during the forecast period. In 2003, Gendicine was
approved in China and was commercialized in 2004. Since then, more than
30,000 patients with head and neck cancers have been treated with
Gendicine, in China. The anticipated approval and launch of gene therapy
products in developed countries, such as Japan, Australia & New
Zealand, and GCC is projected to drive the gene therapy market in this
region.
Majority of biopharmaceutical companies
have made significant investments in the clinical research and
development of gene therapy products. According to a report by the
Alliance for Regenerative Medicine, there were around 34 gene therapy
candidates in phase III clinical trials as of June 2017. Key players
operating in the global market include Gilead Sciences, Inc., Novartis
AG, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., CELGENE
CORPORATION, and Orchard Therapeutics Limited.
No comments:
Post a Comment